CDH5 and neuroblastoma: Recent genome profiling studies in relapsed NB indicated new and acquired recurrent mutations in cadherin 5 (CDH5), dedicator of cytokinesis 8 (DOCK8), protein tyrosine phosphatase non-receptor 14 (PTPN14), HRas proto-oncogene (HRAS), and KRAS proto-oncogene (KRAS), signifying that these acquired mutations contribute to drug resistance and disease evolution[37].